(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 January 2012 (05.01.2012)

PCT

(10) International Publication Number
WO 2012/000356 A1

(51) **International Patent Classification**:
C07D 403/14 (2006.01) ***A61P 35/00*** (2006.01)
A61K 31/517 (2006.01) ***A61P 35/04*** (2006.01)

(21) **International Application Number**:
PCT/CN2011/074637

(22) **International Filing Date**:
25 May 2011 (25.05.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
PCT/CN2010/074792 30 June 2010 (30.06.2010) CN

(71) **Applicant** *(for all designated States except US)*: **HUTCHISON MEDIPHARMA LIMITED** [CN/CN]; Building 4, 720 Cai Lun Road, Pudong New Area, Shanghai 201203 (CN).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **ZHANG, Weihan** [CN/CN]; Building 4, 720 Cai Lun Road, Pudong New Area, Shanghai 201203 (CN). **SU, Wei-Guo** [US/CN]; Building 4, 720 Cai Lun Road, Pudong New Area, Shanghai 201203 (CN). **YANG, Haibin** [CN/CN]; Building 4, 720 Cai Lun Road, Pudong New Area, Shanghai 201203 (CN). **CUI, Yumin** [CN/CN]; Building 4, 720 Cai Lun Road, Pudong New Area, Shanghai 201203 (CN). **REN, Yongxin** [CN/CN]; Building 4, 720 Cai Lun Road, Pudong New Area, Shanghai 201203 (CN). **YAN, Xiaoqiang** [US/CN]; Building 4, 720 Cai Lun Road, Pudong New Area, Shanghai 201203 (CN).

(74) **Agent**: **ZHONGZI LAW OFFICE**; 7F, New Era Building, 26 Pinganli Xidajie, Xicheng District, Xicheng District, Beijing 100034 (CN).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2012/000356 A1

(54) **Title**: QUINAZOLINE COMPOUNDS

(57) **Abstract**: Provided are certain quinazoline compounds, compositions thereof and methods of use thereof. These quinazoline compounds can effectively inhibit the overexpression and/or overactivity of epidermal growth factor receptor (EGFR).